Patent US6181055B1 successfully refreshed from Google Patents.
EP0621338A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Immunosuppressant able to block the interleukin - 2 response
Assignee: Sugamura Kazuo
•
Filing: 1994-04-21
•
Granted: —
•
Expires: 2014-04-21
Abstract
Abstract Provided is a polypeptide which specifically binds to the γ-chain of human interleukin-2 receptor to selectively inhibit the binding of the γ-chain of human interleukin-2 receptor to the β-chain of the same, therefore having an activity of blocking the human interleukin-2 response. Also provided are an immunosuppressant containing the polypeptide, a DNA gene coding for the polypeptide, a recombinant DNA having the gene, a transformant having the recombinant DNA, and a method for producing the objective polypeptide by incubating the transformant. The novel polypeptide is usable, independently or along with substances capable of inhibiting the binding of interleukin-2 to interleukin-2 receptor, as a medicine effective in preventing the rejection of grafts after transplantation and also in curing inflammatory diseases such as allergic diseases and autoimmune diseases, the possibility that interleukin-2 will actively participate in the rejection and also in such inflammatory diseases having been suggested.
Inventors
- 👤 Toshiro C/O Central Research Lab. Shimamura
- 👤 Junji C/O Central Research Lab. Hamura
- 👤 Harumi C/O Central Research Lab. Nakazawa
- 👤 Yuka C/O Central Research Lab. Kanayama
- 👤 Kazuo Sugamura
- 👤 Toshikazu Takeshita
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 03:43
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/715; C07K14/7155; C07K16/00; C07K16/18; C07K16/28; C07K16/2866; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
22 words
A polypeptide, which specifically binds to the γ-chain of the interleukin-2 receptor and has the activity of blocking the interleukin 2 response.
Claim 2
Dependent Claim
17 words
A polypeptide according to Claim 1, which specifically binds to the γ-chain of the human interleukin-2 receptor.
Claim 3
Dependent Claim
14 words
The polypeptide according to Claim 1 or Claim 2, which is a monoclonal antibody.
Claim 4
Dependent Claim
17 words
The polypeptide according to any of the Claims 1 to 3, which is a mouse monoclonal antibody.
Claim 5
Dependent Claim
34 words
The polypeptide according to any of the preceeding Claims, which is a monoclonal antibody produced by the cells GP-2 (FERM BP-4641), GP-4 (FERM BP-4640), TUGh4 (FERM BP-4642), TUGh5 (FERM BP-4643) or AG14 (FERM BP-4648).
Claim 6
Dependent Claim
17 words
A hybridoma capable of producing a monoclonal antibody according to any of the Claims 3 to 5.
Claim 7
Dependent Claim
20 words
The polypeptide according to any of the Claims 1 to 5, which lacks the constant region of a monoclonal antibody.
Claim 8
Dependent Claim
132 words
The polypeptide according to any of the Claims 1 to 5, which is selected from the group consisting of (a) the following amino acid sequence (b) a polypeptide, which in respect to (a) is deficient in one or more amino acids; (c) a polypeptide, in which in respect to (a) or (b) one or more amino acids are replaced; (d) a fusion peptide comprising a polypeptide according to (a), (b) or (c), in which the additively connected amino acids do not interfere with the activity of the polypeptide or which may be easily removed; (e) a polypeptide, which in respect to (a), (b), (c) or (d) lacks the N-terminal Met; (f) a polypeptide, in which in respect to (a), (b), (c), (d) or (e) one ore more amino acids are chemically modified.
Claim 9
Dependent Claim
132 words
The polypeptide according to any of the Claims 1 to 5, which is selected from the group consisting of (a) the following amino acid sequence (b) a polypeptide, which in respect to (a) is deficient in one or more amino acids; (c) a polypeptide, in which in respect to (a) or (b) one or more amino acids are replaced; (d) a fusion peptide comprising a polypeptide according to (a), (b) or (c) in which the additively connected amino acids do not interfere with the activity of the polypeptide or which may be easily removed; (e) a polypeptide, which in respect to (a), (b), (c) or (d) lacks the N-terminal Met; (f) a polypeptide in which in respect to (a), (b), (c), (d) or (e) one ore more amino acids are chemically modified.
Claim 10
Dependent Claim
23 words
The polypeptide according to Claim 8 or 9, in which the chemical modification has been effected by acetylating, amidating or with polyethylene glycol(s).
Claim 11
Dependent Claim
29 words
The polypeptide according to any of the Claims 3 to 5, in which the constant region of the antibody has been replaced by a constant region of another species.
Claim 12
Dependent Claim
27 words
The polypeptide according to Claim 11, in which the constant region of a mouse monoclonal antibody has been replaced by a constant region of a human antibody.
Claim 13
Dependent Claim
19 words
A pharmaceutical composition comprising a polypeptide according to any of the Claims 1 to 5 and 7 to 12.
Claim 14
Dependent Claim
13 words
The pharmaceutical composition according to Claim 13, which additionally contains other active ingredients.
Claim 15
Dependent Claim
161 words
The pharmaceutical composition according to claim 14, in which the additional active ingredients are (i) an anti-human interleukin-2 receptor α-chain antibody and/or the variable region thereof or (ii) an anti-human interleukin-2 receptor γ-chain antibody and/or the variable region thereof and/or (iii) derivatives of (i) and/or (ii) which are selected from the group consisiting of (b) a polypeptide, which in respect to (a) is deficient in one or more amino acids; (c) a polypeptide, in which in respect to (a) or (b) one or more amino acids are replaced; (d) a fusion peptide comprising a polypeptide according to (a), (b) or (c) in which the additively connected amino acids do not interfere with the activity of the polypeptide or which may be easily removed; (e) a polypeptide, which in respect to (a), (b), (c) or (d) lacks the N-terminal Met; (f) a polypeptide in which in respect to (a), (b), (c), (d) or (e) one ore more amino acids are chemically modified.
Claim 16
Dependent Claim
19 words
A DNA coding for a polypeptide according to any of the Claims 1 to 5 and 7 to 12.
Claim 17
Dependent Claim
70 words
The DNA according to Claim 16, which has a nucleotide sequence selected from the group consisting of (a) a DNA-sequence having the following nucleotide sequence (b) a DNA-sequence, which in respect to (a) is deficient in one or more nucleotides; (c) a DNA-sequence, in which in respect to (a) one or more nucleotides are replaced; (d) a DNA-sequence, to which in respect to (a) one or more nucleotides are added.
Claim 18
Dependent Claim
70 words
The DNA according to Claim 16, which has a nucleotide sequence selected from the group consisting of (a) a DNA-sequence having the following nucleotide sequence (b) a DNA-sequence, which in respect to (a) is deficient in one or more nucleotides; (c) a DNA-sequence, in which in respect to (a) one or more nucleotides are replaced; (d) a DNA-sequence, to which in respect to (a) one or more nucleotides are added.
Claim 19
Dependent Claim
15 words
A recombinant DNA comprising a DNA according to any of the Claims 16 to 18.
Claim 20
Dependent Claim
14 words
A vector comprising a DNA according to any of the Claims 16 to 19.
Claim 21
Dependent Claim
10 words
A vector according to Claim 20, which is a plasmid.
Claim 22
Dependent Claim
15 words
A cell transformed with a DNA-sequence according to any of the Claims 16 to 21.
Claim 23
Dependent Claim
10 words
A cell according to Claim 22, which is a procaryote.
Claim 24
Dependent Claim
13 words
A cell according to Claim 22 or Claim 23, which is Escherichia coli.
Claim 25
Dependent Claim
13 words
A cell according to Claim 24, which is FERM BP-4636 or FERM BP-4637.
Claim 26
Dependent Claim
10 words
A cell according to Claim 22 which is an eucaryote.
Claim 27
Dependent Claim
36 words
A method for producing a polypeptide according to any of the Claims 1 to 5 and 7 to 12, which comprises incubating a transformant according to any of Claim 22 to 26 and collecting the polypeptide.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.